[go: up one dir, main page]

AR046245A1 - Sales de calcio de rabeprazol - Google Patents

Sales de calcio de rabeprazol

Info

Publication number
AR046245A1
AR046245A1 ARP030104642A ARP030104642A AR046245A1 AR 046245 A1 AR046245 A1 AR 046245A1 AR P030104642 A ARP030104642 A AR P030104642A AR P030104642 A ARP030104642 A AR P030104642A AR 046245 A1 AR046245 A1 AR 046245A1
Authority
AR
Argentina
Prior art keywords
calcium salts
rabeprazol
rabeprazole
prevention
prepare
Prior art date
Application number
ARP030104642A
Other languages
English (en)
Inventor
Yatendra Kumar
Neela Praveen Kumar
Mohan Prasad
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of AR046245A1 publication Critical patent/AR046245A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sales de Calcio de Rabeprazol, procesos para prepararlas, composiciones farmacéuticas que las contienen, y su uso para el tratamiento o prevención de ulceras gastrointestinales.
ARP030104642A 2002-12-16 2003-12-16 Sales de calcio de rabeprazol AR046245A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1265DE2002 2002-12-16

Publications (1)

Publication Number Publication Date
AR046245A1 true AR046245A1 (es) 2005-11-30

Family

ID=32587698

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104642A AR046245A1 (es) 2002-12-16 2003-12-16 Sales de calcio de rabeprazol

Country Status (6)

Country Link
US (1) US20060122233A1 (es)
EP (1) EP1575937A2 (es)
AR (1) AR046245A1 (es)
AU (1) AU2003288576A1 (es)
BR (1) BR0317425A (es)
WO (1) WO2004055001A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006024890A1 (en) * 2004-08-30 2006-03-09 Apollo International Limited Improved process for rabeprazole sodium in amorphous form
US20080166423A1 (en) * 2007-01-06 2008-07-10 Renjit Sundharadas Combination Medication for Treating the Effects of Stomach Acid Reduction Medication on Bone Integrity
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
WO2008155780A2 (en) * 2007-06-21 2008-12-24 Matrix Laboratories Ltd Improved process for the preparation of pure rabeprazole
KR100910709B1 (ko) 2007-10-23 2009-08-04 일동제약주식회사 라베프라졸 나트륨염 무정형의 개선된 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
CA2295817C (en) * 1997-07-11 2008-02-12 Eisai Co., Ltd. Method for producing pyridine compound
JP2001039975A (ja) * 1999-07-26 2001-02-13 Eisai Co Ltd スルホキシド誘導体の結晶およびその製造法

Also Published As

Publication number Publication date
EP1575937A2 (en) 2005-09-21
WO2004055001A3 (en) 2004-11-04
BR0317425A (pt) 2005-11-16
AU2003288576A1 (en) 2004-07-09
WO2004055001A2 (en) 2004-07-01
US20060122233A1 (en) 2006-06-08
AU2003288576A8 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
BRPI0517088A (pt) formulação de comprimido estável
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
PT2275097T (pt) Composições que incluem canabinoides para tratamento de náuseas, vómitos, émese, enjoo ou condições idênticas
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
UY28122A1 (es) Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
DE50310516D1 (de) Fredericamycin-derivate
SE0301653D0 (sv) Novel compounds
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
MA31145B1 (fr) Composition antivirale et procede d'utilisation
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
NO20072290L (no) Organiske forbindelser.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
GT200600199A (es) Diarilsulfonas sulfonamidas y su uso
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"

Legal Events

Date Code Title Description
FB Suspension of granting procedure